ATE310531T1 - Stabilisierte pharmazeutische zusammensetzungen von hedgehog-proteinen und deren verwendung - Google Patents
Stabilisierte pharmazeutische zusammensetzungen von hedgehog-proteinen und deren verwendungInfo
- Publication number
- ATE310531T1 ATE310531T1 AT99115245T AT99115245T ATE310531T1 AT E310531 T1 ATE310531 T1 AT E310531T1 AT 99115245 T AT99115245 T AT 99115245T AT 99115245 T AT99115245 T AT 99115245T AT E310531 T1 ATE310531 T1 AT E310531T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical compositions
- hedgehog proteins
- stabilized pharmaceutical
- ions
- hedgehog
- Prior art date
Links
- 102000003693 Hedgehog Proteins Human genes 0.000 title abstract 2
- 108090000031 Hedgehog Proteins Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- -1 anionic saccharide Chemical class 0.000 abstract 1
- 229910001424 calcium ion Inorganic materials 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 229910001425 magnesium ion Inorganic materials 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Detergent Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98114851A EP0987028A1 (de) | 1998-08-07 | 1998-08-07 | Pharmazeutische Zusammensetzung von Hedgehog-Proteinen und deren Verwendung |
| EP98116734 | 1998-09-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE310531T1 true ATE310531T1 (de) | 2005-12-15 |
Family
ID=26149508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99115245T ATE310531T1 (de) | 1998-08-07 | 1999-08-02 | Stabilisierte pharmazeutische zusammensetzungen von hedgehog-proteinen und deren verwendung |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6207718B1 (de) |
| EP (1) | EP0978285B1 (de) |
| JP (1) | JP3567103B2 (de) |
| CN (1) | CN1244429A (de) |
| AT (1) | ATE310531T1 (de) |
| AU (1) | AU761341B2 (de) |
| CA (1) | CA2279743C (de) |
| DE (1) | DE69928472T2 (de) |
| DK (1) | DK0978285T3 (de) |
| ES (1) | ES2253851T3 (de) |
| HU (1) | HUP9902655A3 (de) |
| IL (1) | IL131238A (de) |
| MA (1) | MA26667A1 (de) |
| NO (1) | NO993804L (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2312009A1 (en) * | 1997-11-28 | 1999-06-10 | Roche Diagnostics Gmbh | An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes |
| US6897297B1 (en) * | 1997-12-03 | 2005-05-24 | Curis, Inc. | Hydrophobically-modified protein compositions and methods |
| EP1557427A3 (de) * | 1998-04-30 | 2005-10-19 | Curis, Inc. | Hedgehog-Protein-Konjugat |
| EP1025861A1 (de) * | 1999-02-04 | 2000-08-09 | Roche Diagnostics GmbH | Pharmazeutische Zusammensetzung von hydrophob modifizierten Hedgehog-Proteinen und deren Verwendung |
| US20040220103A1 (en) * | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| CA2280925A1 (en) * | 1999-07-29 | 2001-01-29 | Bernard Charles Sherman | Stabilized cefuroxime axetil |
| AU2001255767A1 (en) * | 2000-04-28 | 2001-11-12 | Curis, Inc. | Methods and reagents for tissue engineering of cartilage in vitro |
| EP1947116B1 (de) | 2003-02-10 | 2017-06-21 | 2-BBB Medicines B.V. | Differenziell exprimierte Nukleinsäuren der Blut-Hirnschranke bei einer Entzündung |
| US20070053883A1 (en) * | 2003-03-25 | 2007-03-08 | The Johns Hopkins University | Neuronal cell lineages and methods of production thereof |
| US20070148144A1 (en) * | 2005-10-27 | 2007-06-28 | Mason James M | Gene-enhanced tissue engineering |
| AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| DK2308514T3 (da) | 2007-03-23 | 2013-09-02 | To Bbb Holding B V | Konjugater til målrettet lægemiddeltransport gennem blod-hjerne barrieren |
| US7678764B2 (en) * | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
| EP2170368B1 (de) * | 2007-06-29 | 2011-01-05 | Advanced Technologies and Regenerative Medicine, LLC | Flüssige proteinformulierungen mit gdf-5 zur verwendung bei erhöhten temperaturen |
| US8058237B2 (en) * | 2007-08-07 | 2011-11-15 | Advanced Technologies & Regenerative Medicine, LLC | Stable composition of GDF-5 and method of storage |
| WO2009129101A1 (en) * | 2008-04-14 | 2009-10-22 | Advanced Technologies And Regenerative Medicine, Llc | Liquid buffered gdf-5 formulations |
| WO2010087702A1 (en) | 2009-01-30 | 2010-08-05 | Stichting Katholieke Universiteit | TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject |
| WO2011034421A1 (en) | 2009-09-16 | 2011-03-24 | Stichting Het Nederlands Kanker Instituut | Fra-1 target genes as drug targets for treating cancer |
| EP2305717A1 (de) | 2009-09-21 | 2011-04-06 | Koninklijke Nederlandse Akademie van Wetenschappen | Hemmung von TNIK zur Behandlung von Darmkrebs |
| US9295720B2 (en) | 2010-08-27 | 2016-03-29 | Pantarhei Bioscience B.V. | Immunotherapeutic method for treating prostate cancer |
| EP2465928A1 (de) | 2010-12-16 | 2012-06-20 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Behandlung von Th17-vermittelten Krankheiten |
| US11633458B2 (en) | 2013-11-08 | 2023-04-25 | University Of Virginia Patent Foundation | Compositions and methods for treating melanoma |
| WO2016080830A2 (en) | 2014-11-18 | 2016-05-26 | Pantarhei Bioscience B.V. | Immunotherapeutic method for treating pancreatic cancer |
| US12570981B2 (en) | 2016-03-21 | 2026-03-10 | University Of Virginia Patent Foundation | Genetically modified mouse with conditional deletion of LRP1 in oligodendrocytes |
| JP2019535827A (ja) * | 2016-11-16 | 2019-12-12 | アイビタ バイオメディカル インコーポレイテッド | 細胞膜結合シグナル伝達因子の使用 |
| US20200390678A1 (en) * | 2017-11-16 | 2020-12-17 | Aivita Biomedical, Inc. | Use of cell membrane-bound signaling factors |
| WO2025263459A1 (ja) * | 2024-06-17 | 2025-12-26 | 学校法人神戸薬科大学 | バイオ医薬品組成物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2148901A (en) | 1983-10-04 | 1985-06-05 | Johnson & Johnson | Protein/polysaccharide complexes |
| JPH0725689B2 (ja) | 1986-10-07 | 1995-03-22 | 中外製薬株式会社 | 顆粒球コロニ−刺激因子を含有する徐放性製剤 |
| US5078997A (en) | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| US5156623A (en) | 1990-04-16 | 1992-10-20 | Olympus Optical Co., Ltd. | Sustained release material and method of manufacturing the same |
| US5416071A (en) | 1991-03-12 | 1995-05-16 | Takeda Chemical Industries, Ltd. | Water-soluble composition for sustained-release containing epo and hyaluronic acid |
| DE4126983A1 (de) | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
| US5215758A (en) | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
| US5789543A (en) | 1993-12-30 | 1998-08-04 | President And Fellows Of Harvard College | Vertebrate embryonic pattern-inducing proteins and uses related thereto |
| CA2179029C (en) | 1993-12-30 | 2009-02-24 | Philip W. Ingham | Vertebrate embryonic pattern-inducing hedgehog-like proteins |
| CA2184092A1 (en) * | 1994-02-25 | 1995-08-31 | Thomas M. Jessell | Dna encoding the vertebrate homolog of hedgehog, vhh-1, expressed by the notochord, and uses thereof |
| US5663390A (en) | 1996-08-29 | 1997-09-02 | Libbey-Owens-Ford Co. | Method of producing organo indium chlorides |
| JPH10194987A (ja) * | 1997-01-14 | 1998-07-28 | Youtai Iwamoto | 骨・軟骨形成用組成物 |
| US6656508B2 (en) | 1997-04-17 | 2003-12-02 | Amgen Inc. | Sustained-release alginate gels |
| EP0947201B1 (de) | 1998-02-04 | 2006-06-28 | Curis, Inc. | Pharmazeutische Zusammensetzungen von Hedgehog-Proteinen und deren Verwendung |
| EP0953575A1 (de) | 1998-04-30 | 1999-11-03 | Boehringer Mannheim Gmbh | Aktives Hedgehog-Protein-Konjugat, Verfahren zur Herstellung und Verwendung |
| EP1557427A3 (de) | 1998-04-30 | 2005-10-19 | Curis, Inc. | Hedgehog-Protein-Konjugat |
-
1999
- 1999-08-02 DK DK99115245T patent/DK0978285T3/da active
- 1999-08-02 ES ES99115245T patent/ES2253851T3/es not_active Expired - Lifetime
- 1999-08-02 AT AT99115245T patent/ATE310531T1/de not_active IP Right Cessation
- 1999-08-02 EP EP99115245A patent/EP0978285B1/de not_active Expired - Lifetime
- 1999-08-02 DE DE69928472T patent/DE69928472T2/de not_active Expired - Fee Related
- 1999-08-02 US US09/365,948 patent/US6207718B1/en not_active Expired - Fee Related
- 1999-08-04 MA MA25714A patent/MA26667A1/fr unknown
- 1999-08-04 CA CA002279743A patent/CA2279743C/en not_active Expired - Fee Related
- 1999-08-04 HU HU9902655A patent/HUP9902655A3/hu unknown
- 1999-08-04 IL IL13123899A patent/IL131238A/xx not_active IP Right Cessation
- 1999-08-06 NO NO993804A patent/NO993804L/no not_active Application Discontinuation
- 1999-08-06 CN CN99111979A patent/CN1244429A/zh active Pending
- 1999-08-06 AU AU43448/99A patent/AU761341B2/en not_active Ceased
- 1999-08-09 JP JP22575699A patent/JP3567103B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL131238A0 (en) | 2001-01-28 |
| HK1025740A1 (en) | 2000-11-24 |
| AU761341B2 (en) | 2003-06-05 |
| US6207718B1 (en) | 2001-03-27 |
| IL131238A (en) | 2005-07-25 |
| HU9902655D0 (en) | 1999-10-28 |
| NO993804L (no) | 2000-02-08 |
| DE69928472T2 (de) | 2006-08-10 |
| DK0978285T3 (da) | 2006-03-27 |
| CA2279743C (en) | 2005-05-10 |
| ES2253851T3 (es) | 2006-06-01 |
| EP0978285A1 (de) | 2000-02-09 |
| JP2000063283A (ja) | 2000-02-29 |
| CN1244429A (zh) | 2000-02-16 |
| CA2279743A1 (en) | 2000-02-07 |
| DE69928472D1 (de) | 2005-12-29 |
| NO993804D0 (no) | 1999-08-06 |
| MA26667A1 (fr) | 2004-12-20 |
| EP0978285B1 (de) | 2005-11-23 |
| HUP9902655A3 (en) | 2000-12-28 |
| AU4344899A (en) | 2000-03-02 |
| HUP9902655A2 (hu) | 2000-08-28 |
| JP3567103B2 (ja) | 2004-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE310531T1 (de) | Stabilisierte pharmazeutische zusammensetzungen von hedgehog-proteinen und deren verwendung | |
| ATE290877T1 (de) | Stabilisierte insulin-zubereitungen | |
| DE69939661D1 (de) | Hautdesodorierende und desinfizierende zubereitung | |
| DE60115602D1 (de) | Verwendung von säurestabilen subtilisinproteasen in tierfutter | |
| BR9900685B1 (pt) | composição sólida desodorante e utilização cosmética de uma composição sólida. | |
| BR9913912A (pt) | Métodos e composições para tratamento de doenças mediadas por receptor | |
| CO4910133A1 (es) | Antagonistas de 5-h[1f] | |
| BR0007035A (pt) | Métodos de controle de pragas de agrótis | |
| BR0215405A (pt) | Composições e processos de uso de collajolie | |
| BR9107020A (pt) | Composiçao detergente compreendendo sulfato de alquila e uma ou mais subtilisinas ou variantes de subtilisina. | |
| FR2773486B1 (fr) | Composition de soin des levres contenant de l'acide acexamique, ses utilisations | |
| BR0009502A (pt) | Componente de amaciamento de tecido | |
| ATE260674T1 (de) | Stabilisierte proteinzusammensetzung | |
| BR9910539A (pt) | Derivados de 2 - (2 - clorofenil) - 3,4 - dihidro - 2h - pirrol | |
| TR199903132A3 (tr) | Metalosan bilesiklerinin aktive edici kompozisyonu. | |
| BRPI0403461A (pt) | composições estabilizadas contendo um agente ativo lábil ao oxigênio | |
| ID25478A (id) | Agonis 5-ht1f | |
| DE69936052D1 (de) | N1 modifizierte glycopeptide | |
| BR9916537B1 (pt) | composição de fragráncia, e, produto. | |
| DE59806013D1 (de) | Aktivchlorabspaltender Toilettenreinigungsblock | |
| BR0009469A (pt) | Tablete perfumado de detergente | |
| BR9903555A (pt) | Composição farmacêutica de proteìnas de ouriço e seu uso | |
| BRPI0410150A (pt) | método de neutralizar ou reduzir odores associados com fluidos ou sólidos corporais, uso de uma composição de materiais de fragráncia, e, artigo | |
| BRPI0411435A (pt) | método para controlar mau cheiro, e, composição desodorizante | |
| ID27656A (id) | Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0978285 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |